Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1532P - Nab-paclitaxel plus S1 with or without sintilimab in metastatic pancreatic ductal adenocarcinoma: A single-center, retrospective study

Date

17 Sep 2020

Session

E-Poster Display

Topics

Immunotherapy

Tumour Site

Pancreatic Adenocarcinoma

Presenters

Qu Liu

Citation

Annals of Oncology (2020) 31 (suppl_4): S881-S897. 10.1016/annonc/annonc285

Authors

Q. Liu1, R. Liu1, Z. Zhao1, F. Wang1, Y. Wang1, X. Li2, T. Ma2

Author affiliations

  • 1 Second Department Of Hepatopancreatobiliary Surgery, The General Hospital of People’s Liberation Army/ 301 Hospital, 100853 - Beijing/CN
  • 2 Department Of Translational Medicine, Genetron Health (Beijing) Co. Ltd., 102206 - Beijing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1532P

Background

About 60% of the pancreatic cancers were diagnosed with metastasis and lose surgery opportunity. PD-1 inhibitors have shown a significant efficacy in enhancing anti-tumor immune response in most solid tumors. This retrospective study aimed to explore the efficacy and safety of nab-paclitaxel plus S1 combined with sintilimab, a PD-1 inhibitor, as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).

Methods

Patients with mPDAC who have never received anti-tumor therapy before were enrolled in this study. Treatment for patients in group A consisted of nab-paclitaxel 120 mg/m2 intravenously on days 1 and 8; S-1 80 mg/m2 orally on days 1 to 14 cycled every 3 weeks; treatment for patients in group B was the same as that for patients in group A, and added sintilimab 200 mg intravenously, once every 3 weeks. Surgery was operated when a complete or major radiological response of the liver metastases was overserved. The primary end point was progression-free survival (PFS). Secondary end points were resection rate, overall response rate (ORR), disease control rate (DCR), overall survival (OS) and safety.

Results

From 2017 to 2019, 65 mPDAC unselected patients were included in this study, 34 patients in group A and 31 patients in group B. ORR for group A was 44.1% and 58.1% for group B. DCR was 79.4% for group A and 96.8% for group B (P =0.01). Radical resection was carried out in 14 (21.5%) patients after downstaging of mPDAC, 4 (11.8%) in group A and 10 (32.2%) in group B (P =0.045), altogether 3 (8.8%) patients in group A and 8 (25.8%) in group B achieving R0 (P =0.07). Two patients in group B achieved a complete response (CR). Median PFS was 9.7 months for group A and 10.1 months for group B (P =0.01). Median OS for group A was 15.5 months and was not achieved for group B (P =0.03). The most common adverse events of grade 3 to 4 were neutropenia (32.4% in group A vs. 38.7% in group B), sensory neuropathy (8.8% in group A vs. 9.7% in group B), and elevated AST/ALT (5.9% in group A vs. 12.9% in group B).

Conclusions

Compared with undergoing nab-paclitaxel plus S1 alone, combined with sintilimab showed significantly improved DCR, PFS and OS and a favorable safety profile in mPDAC patients.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

X. Li, T. Ma: Full/Part-time employment: Genetron Health (Beijing) Co. Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.